A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms CheckMate140
- Sponsors Bristol-Myers Squibb
- 05 Aug 2019 Planned End Date changed from 8 Apr 2019 to 30 Nov 2019.
- 15 Oct 2018 Planned End Date changed from 24 Jul 2018 to 8 Apr 2019.
- 07 Jul 2018 This trial has been completed in France.